362 related articles for article (PubMed ID: 9262477)
41. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
[TBL] [Abstract][Full Text] [Related]
42. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling.
Paria BC; Das SK; Dey SK
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9460-4. PubMed ID: 7568154
[TBL] [Abstract][Full Text] [Related]
43. Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex.
Steffens M; Szabo B; Klar M; Rominger A; Zentner J; Feuerstein TJ
Neuroscience; 2003; 120(2):455-65. PubMed ID: 12890515
[TBL] [Abstract][Full Text] [Related]
44. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse.
Lay L; Angus JA; Wright CE
Eur J Pharmacol; 2000 Mar; 391(1-2):151-61. PubMed ID: 10720647
[TBL] [Abstract][Full Text] [Related]
45. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity.
Pan X; Ikeda SR; Lewis DL
Mol Pharmacol; 1998 Dec; 54(6):1064-72. PubMed ID: 9855635
[TBL] [Abstract][Full Text] [Related]
46. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor.
Beltramo M; de Fonseca FR; Navarro M; Calignano A; Gorriti MA; Grammatikopoulos G; Sadile AG; Giuffrida A; Piomelli D
J Neurosci; 2000 May; 20(9):3401-7. PubMed ID: 10777802
[TBL] [Abstract][Full Text] [Related]
47. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction.
Felder CC; Briley EM; Axelrod J; Simpson JT; Mackie K; Devane WA
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7656-60. PubMed ID: 8395053
[TBL] [Abstract][Full Text] [Related]
48. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172.
Fegley D; Kathuria S; Mercier R; Li C; Goutopoulos A; Makriyannis A; Piomelli D
Proc Natl Acad Sci U S A; 2004 Jun; 101(23):8756-61. PubMed ID: 15138300
[TBL] [Abstract][Full Text] [Related]
49. Facilitation of CB1 receptor-mediated neurotransmission decreases marble burying behavior in mice.
Gomes FV; Casarotto PC; Resstel LB; Guimarães FS
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):434-8. PubMed ID: 21111767
[TBL] [Abstract][Full Text] [Related]
50. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro.
Vaughan CW; Connor M; Bagley EE; Christie MJ
Mol Pharmacol; 2000 Feb; 57(2):288-95. PubMed ID: 10648638
[TBL] [Abstract][Full Text] [Related]
51. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors.
Farquhar-Smith WP; Jaggar SI; Rice AS
Pain; 2002 May; 97(1-2):11-21. PubMed ID: 12031775
[TBL] [Abstract][Full Text] [Related]
52. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404.
Giuffrida A; Rodriguez de Fonseca F; Nava F; Loubet-Lescoulié P; Piomelli D
Eur J Pharmacol; 2000 Nov; 408(2):161-8. PubMed ID: 11080522
[TBL] [Abstract][Full Text] [Related]
53. Hypotensive effect of anandamide through the activation of CB1 and VR1 spinal receptors in urethane-anesthetized rats.
del Carmen García M; Adler-Graschinsky E; Celuch SM
Naunyn Schmiedebergs Arch Pharmacol; 2003 Oct; 368(4):270-6. PubMed ID: 14504685
[TBL] [Abstract][Full Text] [Related]
54. AM630, a competitive cannabinoid receptor antagonist.
Pertwee R; Griffin G; Fernando S; Li X; Hill A; Makriyannis A
Life Sci; 1995; 56(23-24):1949-55. PubMed ID: 7776818
[TBL] [Abstract][Full Text] [Related]
55. Effects of cannabinoid receptor agonists on immunologically induced histamine release from rat peritoneal mast cells.
Lau AH; Chow SS
Eur J Pharmacol; 2003 Mar; 464(2-3):229-35. PubMed ID: 12620517
[TBL] [Abstract][Full Text] [Related]
56. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors.
Melck D; Bisogno T; De Petrocellis L; Chuang H; Julius D; Bifulco M; Di Marzo V
Biochem Biophys Res Commun; 1999 Aug; 262(1):275-84. PubMed ID: 10448105
[TBL] [Abstract][Full Text] [Related]
57. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor.
Rinaldi-Carmona M; Barth F; Héaulme M; Shire D; Calandra B; Congy C; Martinez S; Maruani J; Néliat G; Caput D
FEBS Lett; 1994 Aug; 350(2-3):240-4. PubMed ID: 8070571
[TBL] [Abstract][Full Text] [Related]
58. Regulation of subthalamic neuron activity by endocannabinoids.
Morera-Herreras T; Ruiz-Ortega JA; Taupignon A; Baufreton J; Manuel I; Rodriguez-Puertas R; Ugedo L
Synapse; 2010 Sep; 64(9):682-98. PubMed ID: 20336631
[TBL] [Abstract][Full Text] [Related]
59. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock.
Wagner JA; Varga K; Ellis EF; Rzigalinski BA; Martin BR; Kunos G
Nature; 1997 Dec; 390(6659):518-21. PubMed ID: 9394002
[TBL] [Abstract][Full Text] [Related]
60. Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus.
Di S; Boudaba C; Popescu IR; Weng FJ; Harris C; Marcheselli VL; Bazan NG; Tasker JG
J Physiol; 2005 Dec; 569(Pt 3):751-60. PubMed ID: 16239276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
